Ovarian and endometrial function during hormonal contraception

D. T. Baird, J. Collins, I. Cooke, A. Glasier, H. S. Jacobs, C. La Vecchia, G. Stock, P. Vercellini, J. Cohen, P. G. Crosignani, E. Diczfalusy, J. L H Evers, S. Skouby, B. Tarlatzis, B. L. Rubin

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

This report addresses the balance of benefits and risks from changes in ovarian and endometrial function from hormonal contraception. The main mode of action of hormonal contraception is inhibition of ovulation, due chiefly to the dose of oestrogen in combined oral contraceptives. With 20 μg dosages of ethinyl oestradiol follicular activity is more common so that contraception depends on suppression of the LH surge or disruption of the endometrial cycle. In polycystic ovary syndrome (PCOS) treated with oral contraceptives, cysts become smaller and in time the ovarian volume is reduced, ovarian testosterone secretion is reduced and there are potentially favourable effects on carbohydrate and lipid metabolism. Typical oral contraceptive users in the 1980s had a lower incidence of ovarian cysts, but modern oral contraceptives do not appear to affect the incidence of functional cysts or benign epithelial cysts. Moreover, randomized controlled trials indicate that oral contraception prescriptions are unlikely to prevent the development of functional cysts or to hasten their disappearance. Oral contraceptives, however, greatly reduce pelvic pain in women with symptomatic endometriosis and improve the health-related quality of life. Bleeding is a common response with all types of hormonal contraception, but current methodology is inadequate to make accurate comparisons of different products or of different phasic formulations. With continuing use, however, combined oral contraception is associated with endometrial atrophy, the biological plausibility for a reduced risk of endometrial carcinoma. With progestin-only contraception, a number of endometrial changes are considered as possible mechanisms of the associated bleeding but it remains largely unexplained. Oral contraceptives are frequently used for treatment of dysfunctional uterine bleeding, although one trial has been reported. Oral contraceptive use confers protection from endometrial [relative risk (RR) 0.5] and ovarian (RR 0.4) cancers and in both cases, the protection lasts for up to 2 decades after stopping use.

Original languageEnglish
Pages (from-to)1527-1535
Number of pages9
JournalHuman Reproduction
Volume16
Issue number7
Publication statusPublished - 2001

Fingerprint

Contraception
Oral Contraceptives
Cysts
Ovulation Inhibition
Hemorrhage
Contraceptives, Oral, Combined
Ovarian Cysts
Metrorrhagia
Ethinyl Estradiol
Pelvic Pain
Polycystic Ovary Syndrome
Incidence
Carbohydrate Metabolism
Progestins
Endometriosis
Endometrial Neoplasms
Menstrual Cycle
Lipid Metabolism
Atrophy
Prescriptions

Keywords

  • Cancer
  • Endometrial function
  • Oral contraceptives
  • Ovarian function

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Baird, D. T., Collins, J., Cooke, I., Glasier, A., Jacobs, H. S., La Vecchia, C., ... Rubin, B. L. (2001). Ovarian and endometrial function during hormonal contraception. Human Reproduction, 16(7), 1527-1535.

Ovarian and endometrial function during hormonal contraception. / Baird, D. T.; Collins, J.; Cooke, I.; Glasier, A.; Jacobs, H. S.; La Vecchia, C.; Stock, G.; Vercellini, P.; Cohen, J.; Crosignani, P. G.; Diczfalusy, E.; Evers, J. L H; Skouby, S.; Tarlatzis, B.; Rubin, B. L.

In: Human Reproduction, Vol. 16, No. 7, 2001, p. 1527-1535.

Research output: Contribution to journalArticle

Baird, DT, Collins, J, Cooke, I, Glasier, A, Jacobs, HS, La Vecchia, C, Stock, G, Vercellini, P, Cohen, J, Crosignani, PG, Diczfalusy, E, Evers, JLH, Skouby, S, Tarlatzis, B & Rubin, BL 2001, 'Ovarian and endometrial function during hormonal contraception', Human Reproduction, vol. 16, no. 7, pp. 1527-1535.
Baird DT, Collins J, Cooke I, Glasier A, Jacobs HS, La Vecchia C et al. Ovarian and endometrial function during hormonal contraception. Human Reproduction. 2001;16(7):1527-1535.
Baird, D. T. ; Collins, J. ; Cooke, I. ; Glasier, A. ; Jacobs, H. S. ; La Vecchia, C. ; Stock, G. ; Vercellini, P. ; Cohen, J. ; Crosignani, P. G. ; Diczfalusy, E. ; Evers, J. L H ; Skouby, S. ; Tarlatzis, B. ; Rubin, B. L. / Ovarian and endometrial function during hormonal contraception. In: Human Reproduction. 2001 ; Vol. 16, No. 7. pp. 1527-1535.
@article{1a95d7f2f1c6441a8e2e8b2cc0b7a6ec,
title = "Ovarian and endometrial function during hormonal contraception",
abstract = "This report addresses the balance of benefits and risks from changes in ovarian and endometrial function from hormonal contraception. The main mode of action of hormonal contraception is inhibition of ovulation, due chiefly to the dose of oestrogen in combined oral contraceptives. With 20 μg dosages of ethinyl oestradiol follicular activity is more common so that contraception depends on suppression of the LH surge or disruption of the endometrial cycle. In polycystic ovary syndrome (PCOS) treated with oral contraceptives, cysts become smaller and in time the ovarian volume is reduced, ovarian testosterone secretion is reduced and there are potentially favourable effects on carbohydrate and lipid metabolism. Typical oral contraceptive users in the 1980s had a lower incidence of ovarian cysts, but modern oral contraceptives do not appear to affect the incidence of functional cysts or benign epithelial cysts. Moreover, randomized controlled trials indicate that oral contraception prescriptions are unlikely to prevent the development of functional cysts or to hasten their disappearance. Oral contraceptives, however, greatly reduce pelvic pain in women with symptomatic endometriosis and improve the health-related quality of life. Bleeding is a common response with all types of hormonal contraception, but current methodology is inadequate to make accurate comparisons of different products or of different phasic formulations. With continuing use, however, combined oral contraception is associated with endometrial atrophy, the biological plausibility for a reduced risk of endometrial carcinoma. With progestin-only contraception, a number of endometrial changes are considered as possible mechanisms of the associated bleeding but it remains largely unexplained. Oral contraceptives are frequently used for treatment of dysfunctional uterine bleeding, although one trial has been reported. Oral contraceptive use confers protection from endometrial [relative risk (RR) 0.5] and ovarian (RR 0.4) cancers and in both cases, the protection lasts for up to 2 decades after stopping use.",
keywords = "Cancer, Endometrial function, Oral contraceptives, Ovarian function",
author = "Baird, {D. T.} and J. Collins and I. Cooke and A. Glasier and Jacobs, {H. S.} and {La Vecchia}, C. and G. Stock and P. Vercellini and J. Cohen and Crosignani, {P. G.} and E. Diczfalusy and Evers, {J. L H} and S. Skouby and B. Tarlatzis and Rubin, {B. L.}",
year = "2001",
language = "English",
volume = "16",
pages = "1527--1535",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Ovarian and endometrial function during hormonal contraception

AU - Baird, D. T.

AU - Collins, J.

AU - Cooke, I.

AU - Glasier, A.

AU - Jacobs, H. S.

AU - La Vecchia, C.

AU - Stock, G.

AU - Vercellini, P.

AU - Cohen, J.

AU - Crosignani, P. G.

AU - Diczfalusy, E.

AU - Evers, J. L H

AU - Skouby, S.

AU - Tarlatzis, B.

AU - Rubin, B. L.

PY - 2001

Y1 - 2001

N2 - This report addresses the balance of benefits and risks from changes in ovarian and endometrial function from hormonal contraception. The main mode of action of hormonal contraception is inhibition of ovulation, due chiefly to the dose of oestrogen in combined oral contraceptives. With 20 μg dosages of ethinyl oestradiol follicular activity is more common so that contraception depends on suppression of the LH surge or disruption of the endometrial cycle. In polycystic ovary syndrome (PCOS) treated with oral contraceptives, cysts become smaller and in time the ovarian volume is reduced, ovarian testosterone secretion is reduced and there are potentially favourable effects on carbohydrate and lipid metabolism. Typical oral contraceptive users in the 1980s had a lower incidence of ovarian cysts, but modern oral contraceptives do not appear to affect the incidence of functional cysts or benign epithelial cysts. Moreover, randomized controlled trials indicate that oral contraception prescriptions are unlikely to prevent the development of functional cysts or to hasten their disappearance. Oral contraceptives, however, greatly reduce pelvic pain in women with symptomatic endometriosis and improve the health-related quality of life. Bleeding is a common response with all types of hormonal contraception, but current methodology is inadequate to make accurate comparisons of different products or of different phasic formulations. With continuing use, however, combined oral contraception is associated with endometrial atrophy, the biological plausibility for a reduced risk of endometrial carcinoma. With progestin-only contraception, a number of endometrial changes are considered as possible mechanisms of the associated bleeding but it remains largely unexplained. Oral contraceptives are frequently used for treatment of dysfunctional uterine bleeding, although one trial has been reported. Oral contraceptive use confers protection from endometrial [relative risk (RR) 0.5] and ovarian (RR 0.4) cancers and in both cases, the protection lasts for up to 2 decades after stopping use.

AB - This report addresses the balance of benefits and risks from changes in ovarian and endometrial function from hormonal contraception. The main mode of action of hormonal contraception is inhibition of ovulation, due chiefly to the dose of oestrogen in combined oral contraceptives. With 20 μg dosages of ethinyl oestradiol follicular activity is more common so that contraception depends on suppression of the LH surge or disruption of the endometrial cycle. In polycystic ovary syndrome (PCOS) treated with oral contraceptives, cysts become smaller and in time the ovarian volume is reduced, ovarian testosterone secretion is reduced and there are potentially favourable effects on carbohydrate and lipid metabolism. Typical oral contraceptive users in the 1980s had a lower incidence of ovarian cysts, but modern oral contraceptives do not appear to affect the incidence of functional cysts or benign epithelial cysts. Moreover, randomized controlled trials indicate that oral contraception prescriptions are unlikely to prevent the development of functional cysts or to hasten their disappearance. Oral contraceptives, however, greatly reduce pelvic pain in women with symptomatic endometriosis and improve the health-related quality of life. Bleeding is a common response with all types of hormonal contraception, but current methodology is inadequate to make accurate comparisons of different products or of different phasic formulations. With continuing use, however, combined oral contraception is associated with endometrial atrophy, the biological plausibility for a reduced risk of endometrial carcinoma. With progestin-only contraception, a number of endometrial changes are considered as possible mechanisms of the associated bleeding but it remains largely unexplained. Oral contraceptives are frequently used for treatment of dysfunctional uterine bleeding, although one trial has been reported. Oral contraceptive use confers protection from endometrial [relative risk (RR) 0.5] and ovarian (RR 0.4) cancers and in both cases, the protection lasts for up to 2 decades after stopping use.

KW - Cancer

KW - Endometrial function

KW - Oral contraceptives

KW - Ovarian function

UR - http://www.scopus.com/inward/record.url?scp=0034940482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034940482&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1527

EP - 1535

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 7

ER -